• 1
    Modlin IM, Kidd M, Marks IN, et al. The pivotal role of John S. Edkins in the discovery of gastrin. World J Surg 1997; 21: 22634.
  • 2
    Edkins JS. The chemical mechanism of gastric secretion. J Physiol 1906; 46: 1753.
  • 3
    Marshall B. (ed.) Helicobacter Pioneers: Firsthand Accounts from the Scientists Who Discovered Helicobacters, 1892–1982. Oxford, UK: Blackwell, 2002.
  • 4
    Bayliss WM, Starling EH. The mechanism of pancreatic secretion. J Physiol 1902; 28: 32553.
  • 5
    Calam J. The somatostatin-gastrin link of Helicobacter pylori infection. Ann Med 1995; 27: 56973.
  • 6
    Dockray G, Dimaline R, Varro A. Gastrin: old hormone, new functions. Pflugers Arch 2005; 449: 34455.
  • 7
    Takhar AS, Eremin O, Watson SA. The role of gastrin in colorectal carcinogenesis. Surgeon 2004; 2: 5217.
  • 8
    Gilliam AD, Watson SA, Henwood M, et al. A phase II study of G17DT in gastric carcinoma. Eur J Surg Oncol 2004; 30: 53643.
  • 9
    Black JW, Duncan WAH, Durant C, Ganellin CR, Parsons EH. Definition and antagonism of histamine H2-receptors. Nature 1972; 236: 38590.
  • 10
    Kidd M, Hinoue T, Eick G, et al. Global expression analysis of ECL cells in Mastomys natalensis gastric mucosa identifies alterations in the AP-1 pathway induced by gastrin-mediated transformation. Physiol Genomics 2004; 20: 13142.
  • 11
    Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002; 359: 1422.
  • 12
    Leontiadis GI, Sharma VK, Howden CW. Systematic review and meta-analysis of proton pump inhibitor therapy in peptic ulcer bleeding. BMJ 2005; 330: 568.
  • 13
    Bardou M, Toubouti Y, Benhaberou-Brun D, et al. Meta-analysis: Proton-pump inhibition in high-risk patients with acute peptic ulcer bleeding. Aliment Pharmacol Ther 2005; 21: 67786.
  • 14
    Jensen DM, Kovacs TO, Jutabha R, et al. Randomized trial of medical or endoscopic therapy to prevent recurrent ulcer hemorrhage in patients with adherent clots. Gastroenterology 2002; 123: 40713.
  • 15
    Barkun A, Bardou M, Marshall JK. Nonvariceal Upper GI Bleeding Consensus Conference Group. Consensus recommendations for managing patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2003; 139: 84357.
  • 16
    Shah A, Uribe J, Katz PO. Gastroesophageal reflux disease and obesity. Gastroenterol Clin North Am 2005; 34: 3543.
  • 17
    Malfertheiner P. H. pylori eradication does not exacerbate gastro-oesophageal reflux disease. Gut 2004; 53: 3123.
  • 18
    Pandolfino JE, Shi G, Trueworthy B, et al. Esophagogastric junction opening during relaxation distinguishes nonhernia reflux patients, hernia patients, and normal subjects. Gastroenterology 2003; 125: 101824.
  • 19
    Fletcher J, Wirz A, Young J, et al. Unbuffered highly acidic gastric juice exists at the gastroesophageal junction after a meal. Gastroenterology 2001; 121: 77583.
  • 20
    Sifrim D. Relevance of volume and proximal extent of reflux in gastro-esophageal reflux disease. Gut 2005; 54: 1758.
  • 21
    Barlow WJ, Orlando RC. The pathogenesis of heartburn in nonerosive reflux disease: a unifying hypothesis. Gastroenterology 2005; 128: 7718.
  • 22
    Bardhan KD, Stanghellini V, Armstrong D, et al. Evaluation of GERD symptoms during therapy: Part I. Development of the new GERD questionnaire ReQuest. Digestion 2004; 69: 22937.
  • 23
    Talley NJ, Dennis EH, Schettler-Duncan VA, et al. Overlapping upper and lower gastrointestinal symptoms in irritable bowel syndrome patients with constipation or diarrhea. Am J Gastroenterol 2003; 98: 24549.
    Direct Link:
  • 24
    Smart HL, Nicholson DA, Atkinson M. Gastro-oesophageal reflux in the irritable bowel syndrome. Gut 1986; 27: 112731.
  • 25
    Aro P, Ronkainen J, Storskrubb T, et al. Valid symptom reporting at upper endoscopy in a random sample of the Swedish adult general population: the Kalixanda study. Scand J Gastroenterol 2004; 39: 12808.
  • 26
    Shaker R, Castell DO, Schoenfeld PS, et al. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol 2003; 98: 148793.
    Direct Link:
  • 27
    Fass R, Quan SF, O'Connor GT, et al. Predictors of nocturnal heartburn in a large population-based study. Chest 2005; 127: 165866.
  • 28
    Dent J, Armstrong D, Delaney B, et al. Symptom evaluation in reflux disease: workshop background, processes, terminology, recommendations, and discussion outputs. Gut 2004; 53 (Suppl. 4): 124.
  • 29
    Stanghellini V, Armstrong D, Monnikes H, et al. Systematic review: Do we need a new gastro-oesophageal reflux disease questionnaire? Aliment Pharmacol Ther 2004; 19: 46379.
  • 30
    Fraser A, Delaney B, Moayyedi P. Symptom-based outcome measures for dyspepsia and GERD trials: a systematic review. Am J Gastroenterol 2005; 100: 44252.
    Direct Link:
  • 31
    Armstrong D, Monnikes H, Bardhan KD, et al. The construction of a new evaluative GERD questionnaire – methods and state of the art. Digestion 2004; 70: 718.
  • 32
    Bardhan KD, Stanghellini V, Armstrong D, et al. International validation of ReQuest in patients with endoscopy-negative gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2004; 20: 8918.
  • 33
    Monnikes H, Bardhan KD, Stanghellini V, et al. Evaluation of GERD symptoms during therapy: Part II. Psychometric evaluation and validation of the new questionnaire ReQuest in erosive GERD. Digestion 2004; 69: 23844.
  • 34
    Isomoto H, Saenko VA, Kanazawa Y, et al. Enhanced expression of interleukin-8 and activation of nuclear factor kappa-B in endoscopy-negative gastroesophageal reflux disease. Am J Gastroenterol 2004; 99: 58997.
    Direct Link:
  • 35
    Caviglia R, Ribolsi M, Maggiano N, et al. Dilated intercellular spaces of esophageal epithelium in nonerosive reflux disease patients with physiological esophageal acid exposure. Am J Gastroenterol 2005; 100: 5438.
    Direct Link:
  • 36
    Calabrese C, Bortolotti M, Fabbri A, et al. Reversibility of GERD ultrastructural alterations and relief of symptoms after omeprazole treatment. Am J Gastroenterol 2005; 100: 53742.
    Direct Link:
  • 37
    Avidan B, Sonnenberg A, Schnell TG, et al. Acid reflux is a poor predictor for severity of erosive reflux esophagitis. Dig Dis Sci 2002; 47: 256573.
  • 38
    Koek GH, Tack J, Sifrim D, et al. The role of acid and duodenal gastroesophageal reflux in symptomatic GERD. Am J Gastroenterol 2001; 96: 203340.
    Direct Link:
  • 39
    Fass R, Offman JJ, Sampliner RE, et al. The omeprazole test is as sensitive as a 24-hour esophageal pH monitoring in diagnosing gastroesophageal reflux disease (GERD) in symptomatic patients with erosive esophagitis. Aliment Pharmacol Ther 2000; 14: 38996.
  • 40
    Fletcher J, Wirz A, Henry E, McColl KE. Studies of acid exposure immediately above the gastro-oesophageal squamocolumnar junction: evidence of short segment reflux. Gut 2004; 53: 16873.
  • 41
    Bruley des Varannes S, Mion F, Ducrotté P, et al. Simultaneous recordings of esophageal acid exposure with conventional pH monitoring and a wireless system (Bravo). Gut 2005; 54: 16826.
  • 42
    Pandolfino JE, Zhang Q, Schreiner MA, et al. Acid reflux event detection using the Bravo wireless versus the Slimline catheter pH systems: why are the numbers so different? Gut 2005; 54: 168792.
  • 43
    Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798810.
  • 44
    Charbel S, Khandwala F, Vaezi MF. The role of esophageal pH monitoring in symptomatic patients on PPI therapy. Am J Gastroenterol 2005; 100: 2839.
    Direct Link:
  • 45
    Vakil N, Shaw M, Kirby R. Effectiveness of laparoscopic fundoplication in a US community. Am J Med 2003; 114: 15.
  • 46
    McColl KE. When saliva meets acid: chemical warfare at the oesophagogastric junction. Gut 2005; 54: 13.
  • 47
    Carroll L. The Hunting of the Snark. London, UK: Penguin Books, 1967.
  • 48
    Montgomery E, Bronner MP, Goldblum JR, et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol 2001; 32: 36878.
  • 49
    Spechler SJ. Dysplasia in Barrett's esophagus: limitations of current management strategies. Am J Gastroenterol 2005; 100: 92735.
    Direct Link:
  • 50
    Ell C, May A, Gossner L, et al. Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus. Gastroenterology 2000; 118: 6707.